Starzl T E, Demetris A J, Trucco M, Murase N, Ricordi C, Ildstad S, Ramos H, Todo S, Tzakis A, Fung J J
Department of Surgery, University of Pittsburgh Health Science Center, Pennsylvania 15213.
Hepatology. 1993 Jun;17(6):1127-52.
Improvements in the prevention or control of rejection of the kidney and liver have been largely interchangeable (1, 2) and then applicable, with very little modification, to thoracic and other organs. However, the mechanism by which anti rejection treatment permits any of these grafts to be “accepted” has been an immunological enigma (3, 4). We have proposed recently that the exchange of migratory leukocytes between the transplant and the recipient with consequent long-term cellular chimerism in both is the basis for acceptance of all whole-organ allografts and xenografts (5). Although such chimerism was demonstrated only a few months ago, the observations have increased our insight into transplantation immunology and have encouraged the development of alternative therapeutic strategies (6).
在肾脏和肝脏排斥反应的预防或控制方面所取得的进展在很大程度上是可以相互转换的(1,2),并且经过极少的修改后即可应用于胸腔及其他器官。然而,抗排斥治疗使这些移植物中的任何一种得以“被接受”的机制一直是一个免疫学谜团(3,4)。我们最近提出,移植器官与受体之间迁移白细胞的交换以及随之而来的双方长期细胞嵌合现象是所有全器官同种异体移植和异种移植被接受的基础(5)。尽管这种嵌合现象仅在几个月前才得到证实,但这些观察结果加深了我们对移植免疫学的理解,并推动了替代治疗策略的发展(6)。